Big Money Sentiment decreased to 1.21 in 2018 Q4. It has change of 0.13, from 2018Q3’s 1.34. The ratio turned negative due to West Pharmaceutical Services, Inc. positioning: 30 sold and 87 reduced. 44 funds bought positions and 98 increased positions. Investors holded 65.51 million in 2018Q3 but now own 69.84 million shares or 6.61% more.
Fifth Third Bancshares accumulated 2,425 shs. Qs Ltd Llc stated it has 2,706 shs. Amundi Pioneer Asset Management stated it has 0.01% in West Pharmaceutical Services, Inc. (NYSE:WST). 71,886 are held by Kennedy Mngmt. Massachusetts Fincl Company Ma invested in 0.03% or 691,502 shs. Champlain Prns Lc holds 0.57% of its capital in West Pharmaceutical Services, Inc. (NYSE:WST) for 567,985 shs. Cambridge Trust Company stated it has 14,946 shs. Jpmorgan Chase And owns 1.62M shs. Sterling Management Ltd reported 271,673 shs. Neuberger Berman Group Limited Liability Com holds 2.67M shs. Castleark Lc stated it has 0.1% in West Pharmaceutical Services, Inc. (NYSE:WST). Maverick Cap has 99,950 shs for 0.14% of their capital. Hsbc Public Ltd holds 7,182 shs. Kistler holds 49,418 shs. Parkside Financial Bank Tru invested in 837 shs or 0.03% of the stock.
On April, 25. Investors expect West Pharmaceutical Services, Inc. (NYSE:WST) to announce its quarterly earnings, Zacks reports. EPS of $0.66 is 6.45 % up from 2018’s $0.62 EPS. The profit will be $48.66 million for WST if $0.66 EPS becomes true. -9.59 % negative EPS growth is what analysts predict. $0.73 EPS was reported for previous quarter. WST is touching $105.5 during the last trading session, after increased 0.51%.West Pharmaceutical Services, Inc. has volume of 301,352 shares. Since March 27, 2018 WST has risen 22.60% and is uptrending. WST outperformed by 18.23% the S&P 500.
West Pharmaceutical Services, Inc. manufactures and sells packaging components and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally.The company has $7.78 billion market cap. The company??s Proprietary Products segment offers stoppers and seals for injectable packaging systems; and syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies.The P/E ratio is 38.5. It also provides drug containment solutions, including CZ vials, syringes, and cartridges; and self-injection systems, as well as specialized testing services for drug packaging, devices, and administration systems.
Another two news for West Pharmaceutical Services, Inc. (NYSE:WST) were briefly published by: Prnewswire.com on March 08, 2019 with title “West Opens New Digital Technology Center in Bengaluru, India – PRNewswire”. The other Seekingalpha.com‘s article was titled “Dividend Champion Spotlight: West Pharmaceutical Services – Seeking Alpha” and published on November 17, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.